Giant cell arteritis is a serious inflammatory condition affecting blood vessels that requires urgent medical attention and long-term treatment to prevent vision loss and other severe complications, with therapies ranging from high-dose corticosteroids to newer biological medications now being tested in clinical research.

Understanding Treatment Goals in Giant Cell Arteritis

When a person receives a diagnosis of giant cell arteritis, also known as temporal arteritis, beginning treatment quickly becomes the most critical priority. The primary goal of therapy is to prevent serious complications, especially permanent blindness, which can occur suddenly and without warning in untreated patients. Treatment also aims to reduce inflammation in the blood vessels, relieve painful symptoms such as severe headaches and jaw pain, and help patients maintain their quality of life while managing this chronic condition^[1][2].

The treatment approach depends on several factors including the severity of symptoms, whether vision is already affected, and how each patient responds to medications. Some people experience dramatic improvement within just a few days of starting therapy, while others require months or even years of careful medication management. Because giant cell arteritis is a condition that can return even after successful treatment, ongoing monitoring and adjustments to therapy are essential parts of long-term care^[3].

Medical societies around the world have developed treatment guidelines based on decades of clinical experience with this condition. These standard approaches form the foundation of care. At the same time, researchers continue to explore new therapeutic options through clinical trials, offering hope for treatments with fewer side effects and better long-term outcomes. Understanding both established and experimental treatments helps patients and their doctors make informed decisions about managing this challenging disease^[6].

Standard Treatment: Corticosteroids as First-Line Therapy

Corticosteroids, particularly prednisone, have been the cornerstone of giant cell arteritis treatment for many decades. These powerful anti-inflammatory medications work by suppressing the body’s immune system, which is attacking the blood vessels in this condition. When giant cell arteritis is suspected, doctors typically start treatment immediately, even before all diagnostic tests are complete, because delaying therapy by even one or two days can result in irreversible vision loss^[3][7].

The standard starting dose for most patients is between 40 and 60 milligrams of prednisone taken by mouth each day. However, patients who present with visual symptoms or who have already experienced some vision loss may receive higher doses, ranging from 80 to 100 milligrams daily, or may be given intravenous corticosteroids such as methylprednisolone at doses of 1000 milligrams per day for three consecutive days. The choice between oral and intravenous administration depends on the urgency of the situation and the severity of symptoms^[3][16].

Patients typically notice improvement in their symptoms remarkably quickly. Headaches often diminish within 24 to 72 hours, and feelings of fatigue and general unwellness begin to fade. Blood tests that measure inflammation, such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), usually show improvement within days to weeks. Once symptoms are controlled and inflammation markers normalize, the corticosteroid dose is gradually reduced over time. This tapering process is carefully managed because reducing the dose too quickly can allow the disease to flare up again^[3][10].

For most patients, the initial high dose of prednisone is maintained for about one month. After that, doctors slowly decrease the dose over several months, aiming to reach a maintenance level of 5 to 10 milligrams per day. Many patients are able to stop taking prednisone completely after one to two years of treatment, though some require longer therapy. Unfortunately, the disease returns in a significant number of patients even after successful initial treatment, requiring doctors to increase the medication dose again^[3][13].

In addition to corticosteroids, many doctors recommend that patients with giant cell arteritis take low-dose aspirin (typically 81 milligrams daily) unless there are medical reasons not to do so. Research suggests that aspirin may help prevent vision loss and reduce the risk of stroke in people with this condition, though it does not treat the inflammation itself. The aspirin works by preventing blood clots from forming in the narrowed, inflamed arteries^[16].

Advancing Care: Treatment Options in Clinical Trials

Because long-term corticosteroid therapy causes so many problems, researchers have been working to find alternative or additional treatments that could allow patients to use lower doses of prednisone or stop corticosteroids sooner. Several promising medications are now being studied in clinical trials at various stages of development, offering hope for better management of giant cell arteritis with fewer side effects.

Tocilizumab: An Approved Alternative

Tocilizumab is the first and currently only medication specifically approved for treating giant cell arteritis beyond corticosteroids. This drug was approved by medical regulators in May 2017. Tocilizumab is a type of biological therapy called an interleukin-6 (IL-6) receptor antagonist. It works by blocking a protein called interleukin-6, which plays a key role in the inflammation process that damages blood vessels in giant cell arteritis^[3][13].

Tocilizumab can be given in two ways: through an intravenous infusion into a vein, or through a subcutaneous injection under the skin. The subcutaneous form allows patients to give themselves injections at home, usually once per week. Clinical trials showed that tocilizumab helps patients achieve and maintain remission while using significantly lower doses of corticosteroids compared to patients treated with steroids alone. This means patients can avoid many of the harmful side effects of long-term high-dose corticosteroid therapy^[3][17].

The main purpose of adding tocilizumab to treatment is to allow doctors to reduce the corticosteroid dose more quickly and safely, a strategy called “steroid-sparing.” In clinical studies, patients receiving tocilizumab were more successful at tapering off prednisone and staying in remission compared to those taking prednisone alone. The drug is generally well-tolerated, though like all medications, it can have side effects including increased risk of infections, elevated cholesterol levels, and liver enzyme changes^[15].

Other Biological Therapies Under Investigation

Several other biological medications are being tested in clinical trials for giant cell arteritis. Abatacept is one such drug that works differently from tocilizumab. It blocks the activation of immune cells called T-cells, which are thought to contribute to the blood vessel inflammation in giant cell arteritis. Early studies have shown promising results, with some patients able to reduce their corticosteroid doses while maintaining disease control^[15].

Baricitinib and upadacitinib are medications called JAK inhibitors (Janus kinase inhibitors). These drugs block certain enzymes inside cells that are involved in the inflammation process. Because they target multiple inflammatory pathways at once, researchers hope they might be particularly effective for giant cell arteritis. These medications are taken by mouth as pills rather than as injections, which some patients may find more convenient. Clinical trials are currently evaluating their safety and effectiveness in people with giant cell arteritis^[15].

Mavrilimumab is another biological drug being studied in clinical trials. It targets a protein called GM-CSF (granulocyte-macrophage colony-stimulating factor), which activates certain immune cells involved in inflammation. Early research suggests this medication might help control the disease while reducing the need for high-dose corticosteroids^[15].

Secukinumab and ustekinumab are biological therapies that block other inflammatory proteins called interleukins (specifically IL-17 and IL-12/23). These drugs are already approved for treating other inflammatory conditions such as psoriasis and psoriatic arthritis. Researchers are now testing whether they might also be effective for giant cell arteritis. Anakinra, which blocks interleukin-1, is another medication being explored in small studies of patients with this condition^[15].

Understanding Clinical Trial Phases

Clinical trials for new medications progress through several phases, each designed to answer specific questions about a treatment’s safety and effectiveness. Phase I trials are the first studies in humans and focus primarily on safety. Researchers carefully monitor a small number of patients to determine safe doses and watch for side effects. These trials help establish how the body processes the medication and whether it causes any serious harm^[6].

Phase II trials involve larger groups of patients and begin to evaluate whether the treatment actually works. Researchers measure specific outcomes such as reduction in disease activity, improvement in symptoms, and the ability to lower corticosteroid doses. These trials also continue to monitor for side effects and determine the optimal dose of the medication. Phase II trials help researchers decide whether a treatment is promising enough to move forward to larger, more expensive studies^[6].

Phase III trials are large-scale studies that compare the new treatment directly against the current standard of care or a placebo (inactive treatment). These trials provide the strongest evidence about whether a new medication is truly effective and safe. They typically involve hundreds of patients treated at multiple medical centers, sometimes across different countries. The results of Phase III trials are what regulatory agencies such as the FDA in the United States use to decide whether to approve a new medication for use in clinical practice^[6].

Phase IV trials occur after a medication has been approved and is being used in regular clinical practice. These studies monitor for rare side effects that might not have been detected in earlier trials, evaluate how well the medication works in real-world settings, and may explore new uses or dosing strategies. Phase IV research helps doctors understand the long-term benefits and risks of a treatment^[6].

Traditional Immunosuppressive Medications

In addition to newer biological therapies, some doctors use older immunosuppressive medications to help manage giant cell arteritis. Methotrexate is one such drug that has been studied in several clinical trials. It works by suppressing the immune system through different mechanisms than corticosteroids. Some studies have shown that adding methotrexate to prednisone allows patients to taper off steroids more successfully and reduces the rate of disease relapse. However, results have been mixed, and not all studies have found methotrexate to be beneficial. When used, methotrexate is typically taken once weekly as a pill or injection^[16].

Other immunosuppressive medications such as azathioprine, mycophenolate, and leflunomide have been used in some patients, particularly those who cannot tolerate corticosteroids or who have disease that keeps coming back despite standard treatment. However, the evidence supporting these medications is less robust than for corticosteroids and tocilizumab, and they are generally considered when other options have not worked well^[12].

Additional Support and Monitoring

Managing giant cell arteritis involves more than just taking medications. Regular follow-up appointments are essential to monitor disease activity, adjust medication doses, and watch for side effects. Patients typically see their doctors frequently in the first few weeks after diagnosis, then less often as the disease comes under control. At each visit, doctors assess symptoms, perform physical examinations, and order blood tests to measure inflammation markers^[3].

Because corticosteroids can weaken bones, doctors often recommend a bone density test to screen for osteoporosis. Patients may be prescribed calcium and vitamin D supplements, and some may need bisphosphonate medications to protect against bone loss and fractures. Regular eye examinations are important even after treatment begins, as vision problems can occasionally develop despite therapy^[3][13].

Diet and lifestyle modifications can help minimize some of the side effects of corticosteroid therapy. Eating a balanced diet rich in calcium and vitamin D supports bone health. Regular weight-bearing exercise, such as walking, also helps maintain bone strength and can counteract some of the weight gain associated with corticosteroids. However, patients should discuss any exercise program with their doctors to ensure it is safe for their individual situation^[17].

Many patients benefit from connecting with support groups where they can share experiences with others managing the same condition. Living with a chronic illness that requires long-term medication can be emotionally challenging. Some people experience mood changes related to the disease itself or as a side effect of corticosteroids. Speaking with healthcare professionals about these concerns and, when needed, seeking counseling or mental health support can be an important part of comprehensive care^[17].

Most common treatment methods

• Corticosteroid therapy
  • Oral prednisone at doses of 40-60 mg daily for most patients, higher doses of 80-100 mg for those with visual symptoms
  • Intravenous methylprednisolone at 1000 mg daily for three days for patients with acute vision changes
  • Gradual dose reduction after symptom control, typically over months to years
  • Maintenance doses of 5-10 mg daily before attempting to discontinue therapy
  • Treatment duration typically ranges from one to two years, though some patients require longer therapy
• Biological therapy
  • Tocilizumab, an IL-6 receptor antagonist, given as intravenous infusion or subcutaneous injection
  • Used to reduce corticosteroid requirements and maintain remission
  • Currently the only biological medication approved specifically for giant cell arteritis
• Supportive medications
  • Low-dose aspirin (81 mg daily) to reduce risk of vision loss and stroke
  • Vitamin D and calcium supplements for bone protection
  • Bisphosphonate medications to prevent osteoporosis
  • Proton pump inhibitors to protect against stomach problems from corticosteroids
• Investigational therapies in clinical trials
  • Abatacept, which blocks T-cell activation
  • JAK inhibitors such as baricitinib and upadacitinib
  • Mavrilimumab, targeting GM-CSF
  • Other interleukin blockers including secukinumab, ustekinumab, and anakinra
  • Traditional immunosuppressive drugs like methotrexate for steroid-sparing effects